Last reviewed · How we verify
NCT06357845
Linking Somatic Mutation Rate With Baseline Exposure in East Palestine
NA trial testing Survey in Somatic Mutation in 500 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | Case Comprehensive Cancer Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 500 |
| Start date | 16 August 2024 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Survey
- Biological specimen collection
- Communications about study updates and future research opportunities
- Qualitative interview
Conditions studied
- Somatic Mutation — all drugs for Somatic Mutation →
Sponsor
Case Comprehensive Cancer Center — full company profile →
Who can join
18 and older, any sex, with Somatic Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to This research team is conducting this study to develop methods to measure the biological impact of exposure to the chemicals released following the February 3, 2023 train derailment on residents of East Palestine, Ohio, and surrounding communities. The main question it aims to answer is: * What biological impact will be measured based on DNA damage? * In participants who provide a biospecimen, how are biomarker changes related to proximity to the derailment and variations in residents' health histories and behaviors? Participants will: * Complete a brief survey asking about experiences related to the February 3, 2023 train derailment, health experiences, and concerns following the derailment, and background information regarding health history. * Possibly contribute biospecimens such as blood, spit, hair, and/or toenail clippings. * Receive communication about study updates and future research opportunities. * A total of 40 study participants will be recruited to participate in a 90-minute interview. The interviews will be video and audio recorded.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06357845
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Survey
Trials testing the same drug.
- NCT07452159 — Diabetes In Asians at Risk in Youth · not yet recruiting
- NCT07294703 — Factors Associated With Breast Cancer Risks and Outcomes · recruiting
- NCT07330739 — Kinesiophobia in Women With Stress Urinary Incontinence · active not recruiting
- NCT07215039 — Improving Prison Health Equity Through Cancer Literacy and Screening Awareness in Florida · enrolling by invitation
- NCT07220096 — Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Pati · recruiting
Other recruiting trials for Somatic Mutation
Currently open trials in the same condition.
- NCT06054295 — Somatic Mosaicism in Twins Discordant for Childhood Cancer · recruiting
- NCT05735717 — MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies · Phase 2 · recruiting
- NCT05364294 — Molecular Diagnosis of Systemic Autoinflammatory Diseases · recruiting
Other Case Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) · NA · not yet recruiting
- NCT07167056 — Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer · NA · recruiting
- NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
- NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
- NCT07044362 — Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06357845 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Case Comprehensive Cancer Center
- Last refreshed: 16 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06357845.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing